Multidimensional phenotyping of breast cancer cell lines to guide preclinical research
Authors:
- Jodi M. SaunusJSJodi M. Saunus
- Chanel E. SmartCSChanel E. Smart
- Jamie R. KutasovicJKJamie R. Kutasovic
- Rebecca L. JohnstonRJRebecca L. Johnston
- Priyakshi Kalita-De CroftPCPriyakshi Kalita-De Croft
- Mariska MirandaMMMariska Miranda
- Esdy N. RozaliEREsdy N. Rozali
- Ana Cristina VargasAVAna Cristina Vargas
- Lynne E. ReidLRLynne E. Reid
- Eva LorsyELEva Lorsy
- Sibylle CocciardiSCSibylle Cocciardi
- Tatjana SeidensTSTatjana Seidens
Open Access
- 9 September 2017
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 167 (1) , 289-301
Abstract
Purpose Cell lines are extremely useful tools in breast cancer research. Their key benefits include a high degree of control over experimental variables and reproducibility. However, the advantages must be balanced against the limitations of modelling such a complex disease in vitro. Informed selection of cell line(s) for a given experiment now requires essential knowledge about molecular and phenotypic context in the culture dish. Methods We performed multidimensional profiling of 36 widely used breast cancer cell lines that were cultured under standardised conditions. Flow cytometry and digital immunohistochemistry were used to compare the expression of 14 classical breast cancer biomarkers related to intrinsic molecular profiles and differentiation states: EpCAM, CD24, CD49f, CD44, ER, AR, HER2, EGFR, E-cadherin, p53, vimentin, and cytokeratins 5, 8/18 and 19. Results This cell-by-cell analysis revealed striking heterogeneity within cultures of individual lines that would be otherwise obscured by analysing cell homogenates, particularly amongst the triple-negative lines. High levels of p53 protein, but not RNA, were associated with somatic mutations (p = 0.008). We also identified new subgroups using the nanoString PanCancer Pathways panel (730 transcripts representing 13 canonical cancer pathways). Unsupervised clustering identified five groups: luminal/HER2, immortalised (‘normal’), claudin-low and two basal clusters, distinguished mostly by baseline expression of TGF-beta and PI3-kinase pathway genes. Conclusion These features are compared with other published genotype and phenotype information in a user-friendly reference table to help guide selection of the most appropriate models for in vitro and in vivo studies, and as a framework for classifying new patient-derived cancer cell lines and xenografts.Keywords
Funding Information
- National Health and Medical Research Council (APP1017028, APP1113867, APP1082458)
- Australian Research Council (FT130101417)
- National Breast Cancer Foundation (F'ship)
This publication has 26 references indexed in Scilit:
- In Vitro Analysis of Breast Cancer Cell Line Tumourspheres and Primary Human Breast Epithelia Mammospheres Demonstrates Inter- and Intrasphere HeterogeneityPLOS ONE, 2013
- Density-dependent lineage instability of MDA-MB-435 breast cancer cellsOncology Letters, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in CancerNucleic Acids Research, 2010
- Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Research, 2010
- HER3 and downstream pathways are involved in colonization of brain metastases from breast cancerBreast Cancer Research, 2010
- Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathwaysBreast Cancer Research, 2010
- Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapyBreast Cancer Research, 2008
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006